NDTV Profit

Zydus Cadila Gets US Regulator's Nod To Sell Blood Pressure Drug

The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.
EMAIL
COMMENTS
Zydus Cadila group has more than 150 approvals
Zydus Cadila group has more than 150 approvals
New Delhi: Cadila Healthcare on Saturday said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood pressure medicine - Amlodipine and Olmesartan Medoxomil tablets. The nod by US Food and Drug Administration (FDA) is for multiple strengths of the tablets 5mg/40mg; 10mg/20mmg and 10mg/40 mg, the company said in a filing to the Bombay Stock Exchange (BSE). "The drug is indicated for the treatment of hypertension, alone or with other anti-hypertensive agents to lower blood pressure and will be manufactured at the group's formulations manufacturing facility at Pharma SEZ Ahmedabad," Cadila Healthcare added.

The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.

For latest news on Business, like us on Facebook and follow us on Twitter.
ALSO READ For First Time, Mukesh Ambani Discloses Earnings For Jio

Advertisement

Advertisement

GAINERS / LOSERS